Jemima Seidenberg1, Mara Stellato1, Amela Hukara1, Burkhard Ludewig2,3, Karin Klingel4, Oliver Distler1, Przemysław Błyszczuk1,5, Gabriela Kania1. 1. Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, 8952 Schlieren, Switzerland. 2. Institute of Immunobiology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland. 3. Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland. 4. Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tubingen, D-72076 Tubingen, Germany. 5. Department of Clinical Immunology, Jagiellonian University Medical College, 30-663 Krakow, Poland.
Abstract
BACKGROUND: Pathological activation of cardiac fibroblasts is a key step in development and progression of cardiac fibrosis and heart failure. This process has been associated with enhanced autophagocytosis, but molecular mechanisms remain largely unknown. METHODS AND RESULTS: Immunohistochemical analysis of endomyocardial biopsies showed increased activation of autophagy in fibrotic hearts of patients with inflammatory cardiomyopathy. In vitro experiments using mouse and human cardiac fibroblasts confirmed that blockade of autophagy with Bafilomycin A1 inhibited fibroblast-to-myofibroblast transition induced by transforming growth factor (TGF)-β. Next, we observed that cardiac fibroblasts obtained from mice overexpressing transcription factor Fos-related antigen 2 (Fosl-2tg) expressed elevated protein levels of autophagy markers: the lipid modified form of microtubule-associated protein 1A/1B-light chain 3B (LC3BII), Beclin-1 and autophagy related 5 (Atg5). In complementary experiments, silencing of Fosl-2 with antisense GapmeR oligonucleotides suppressed production of type I collagen, myofibroblast marker alpha smooth muscle actin and autophagy marker Beclin-1 in cardiac fibroblasts. On the other hand, silencing of either LC3B or Beclin-1 reduced Fosl-2 levels in TGF-β-activated, but not in unstimulated cells. Using a cardiac hypertrophy model induced by continuous infusion of angiotensin II with osmotic minipumps, we confirmed that mice lacking either Fosl-2 (Ccl19CreFosl2flox/flox) or Atg5 (Ccl19CreAtg5flox/flox) in stromal cells were protected from cardiac fibrosis. CONCLUSION: Our findings demonstrate that Fosl-2 regulates autophagocytosis and the TGF-β-Fosl-2-autophagy axis controls differentiation of cardiac fibroblasts. These data provide a new insight for the development of pharmaceutical targets in cardiac fibrosis.
BACKGROUND: Pathological activation of cardiac fibroblasts is a key step in development and progression of cardiac fibrosis and heart failure. This process has been associated with enhanced autophagocytosis, but molecular mechanisms remain largely unknown. METHODS AND RESULTS: Immunohistochemical analysis of endomyocardial biopsies showed increased activation of autophagy in fibrotic hearts of patients with inflammatory cardiomyopathy. In vitro experiments using mouse and human cardiac fibroblasts confirmed that blockade of autophagy with Bafilomycin A1 inhibited fibroblast-to-myofibroblast transition induced by transforming growth factor (TGF)-β. Next, we observed that cardiac fibroblasts obtained from mice overexpressing transcription factor Fos-related antigen 2 (Fosl-2tg) expressed elevated protein levels of autophagy markers: the lipid modified form of microtubule-associated protein 1A/1B-light chain 3B (LC3BII), Beclin-1 and autophagy related 5 (Atg5). In complementary experiments, silencing of Fosl-2 with antisense GapmeR oligonucleotides suppressed production of type I collagen, myofibroblast marker alpha smooth muscle actin and autophagy marker Beclin-1 in cardiac fibroblasts. On the other hand, silencing of either LC3B or Beclin-1 reduced Fosl-2 levels in TGF-β-activated, but not in unstimulated cells. Using a cardiac hypertrophy model induced by continuous infusion of angiotensin II with osmotic minipumps, we confirmed that mice lacking either Fosl-2 (Ccl19CreFosl2flox/flox) or Atg5 (Ccl19CreAtg5flox/flox) in stromal cells were protected from cardiac fibrosis. CONCLUSION: Our findings demonstrate that Fosl-2 regulates autophagocytosis and the TGF-β-Fosl-2-autophagy axis controls differentiation of cardiac fibroblasts. These data provide a new insight for the development of pharmaceutical targets in cardiac fibrosis.
Authors: Qing Jun Wang; Yaomei Ding; D Stave Kohtz; Stave Kohtz; Noboru Mizushima; Ileana M Cristea; Michael P Rout; Brian T Chait; Yun Zhong; Nathaniel Heintz; Zhenyu Yue Journal: J Neurosci Date: 2006-08-02 Impact factor: 6.167
Authors: Ken Cadwell; Khushbu K Patel; Nicole S Maloney; Ta-Chiang Liu; Aylwin C Y Ng; Chad E Storer; Richard D Head; Ramnik Xavier; Thaddeus S Stappenbeck; Herbert W Virgin Journal: Cell Date: 2010-06-25 Impact factor: 41.582
Authors: Ashley R Winslow; Chien-Wen Chen; Silvia Corrochano; Abraham Acevedo-Arozena; David E Gordon; Andrew A Peden; Maike Lichtenberg; Fiona M Menzies; Brinda Ravikumar; Sara Imarisio; Steve Brown; Cahir J O'Kane; David C Rubinsztein Journal: J Cell Biol Date: 2010-09-20 Impact factor: 10.539
Authors: S Ghavami; R H Cunnington; S Gupta; B Yeganeh; K L Filomeno; D H Freed; S Chen; T Klonisch; A J Halayko; E Ambrose; R Singal; I M C Dixon Journal: Cell Death Dis Date: 2015-03-19 Impact factor: 8.469